ASCO26: Platinum-resistant ADC leader Elahere stumbles in platinum-sensitive disease - Pharmaceutical Technology

The MIROVA miss dampens prospects for Elahere's near-term label expansion into platinum-sensitive disease. The MIROVA miss dampens prospects for Elahere's near-term label expansion into platinum-sensitive disease. AbbVie’s Elahere (mirvetuximab soravtansine-gynx), a first-in-class folate receptor alpha (FRα)-directed antibody-drug conjugate (ADC), continues to gain momentum in ovarian cancer and is currently the only FRα-targeted ADC approved in platinum-resistant disease. Image credit: [Kateryna Kon]/Shutterstock.com Platinum-sensitive ovarian cancer (PSOC) remains difficult to treat despite its responsiveness to mainstay platinum-based chemotherapies, as cumulative toxicities and diminishing treatment durability emerge with each recurrence. AbbVie’s Elahere (mirvetuximab soravtansine-gynx), a first-in-class folate receptor alpha (FRα)-directed antibody-drug conjugate (ADC),…

Source: Pharmaceutical Technology